INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechno...
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020&nb...